{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:03Z","timestamp":1794047343802,"version":"4.8.0"},"reference-count":28,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>No biomarker panel is established for prediction of sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD), a major complication of allogeneic stem cell transplantation (alloSCT). We compared the potential of the Endothelial Activation and Stress Index (EASIX), based on lactate dehydrogenase, creatinine, and thrombocytes, with that of the SOS\/VOD CIBMTR clinical risk score to predict SOS\/VOD in two independent cohorts. In a third cohort, we studied the impact of endothelium-active prophylaxis with pravastatin and ursodeoxycholic acid (UDA) on SOS\/VOD risk. The cumulative incidence of SOS\/VOD within 28 days after alloSCT in the training cohort (Berlin, 2013-2015, n=446) and in the validation cohort (Heidelberg, 2002-2009, n=380) was 9.6% and 8.4%, respectively. In both cohorts, EASIX assessed at the day of alloSCT (EASIX-d0) was significantly associated with SOS\/VOD incidence (p&lt;0.0001), overall survival (OS) and non-relapse mortality (NRM). In contrast, the CIBMTR score showed no statistically significant association with SOS\/VOD incidence, and did not predict OS and NRM. In patients receiving pravastatin\/UDA, the cumulative incidence of SOS\/VOD was significantly lower at 1.7% (p&lt;0.0001, Heidelberg, 2010-2015, n=359) than in the two cohorts not receiving pravastatin\/UDA. The protective effect was most pronounced in patients with high EASIX-d0. The cumulative SOS\/VOD incidence in the highest EASIX-d0 quartiles were 18.1% and 16.8% in both cohorts without endothelial prophylaxis as compared to 2.2% in patients with pravastatin\/UDA prophylaxis (p&lt;0.0001). EASIX-d0 is the first validated biomarker for defining a subpopulation of alloSCT recipients at high risk for SOS\/VOD. Statin\/UDA endothelial prophylaxis could constitute a prophylactic measure for patients at increased SOS\/VOD risk.<\/jats:p>","DOI":"10.3324\/haematol.2019.238790","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T15:44:23Z","timestamp":1579794263000},"page":"446-453","source":"Crossref","is-referenced-by-count":80,"title":["Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel"],"prefix":"10.3324","volume":"106","author":[{"family":"Sihe Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Olaf Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tobias Terzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David Schult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Joshua Majer-Lauterbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Aleksandar Radujkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Igor W. Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lars Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Carsten M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Peter Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Thomas Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"20140","doi-asserted-by":"crossref","unstructured":"Mohty M, Malard F, Abecassis M. Sinusoidal obstruction syndrome\/venoocclusive disease: current situation and perspectives - a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015; 50(6):781-789.","DOI":"10.1038\/bmt.2015.52"},{"key":"20141","doi-asserted-by":"crossref","unstructured":"Mcdonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984; 4(1):116-122.","DOI":"10.1002\/hep.1840040121"},{"key":"20142","doi-asserted-by":"crossref","unstructured":"Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2014; 168(4):481-491.","DOI":"10.1111\/bjh.13215"},{"key":"20143","doi-asserted-by":"crossref","unstructured":"Mohty M, Malard F, Abecassis M. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/venoocclusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016; 51(7):906-912.","DOI":"10.1038\/bmt.2016.130"},{"key":"20144","doi-asserted-by":"crossref","unstructured":"Jones RJ, Lee KS, Beschorner WE. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987; 44(6):778-783.","DOI":"10.1097\/00007890-198712000-00011"},{"key":"20145","doi-asserted-by":"crossref","unstructured":"McDonald GB, Hinds MS, Fisher LD. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993; 118(4):255-267.","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"20146","unstructured":"Carreras E, Bertz H, Arcese W. Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood. 1998; 92(10):3599-3604."},{"key":"20147","doi-asserted-by":"crossref","unstructured":"Coppell JA, Richardson PG, Soiffer R. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010; 16(2):157-168.","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"20148","doi-asserted-by":"crossref","unstructured":"Dalle J-H, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016; 22(3):400-409.","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"20149","doi-asserted-by":"crossref","unstructured":"Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011; 46(12):1495-1502.","DOI":"10.1038\/bmt.2011.65"},{"key":"20150","doi-asserted-by":"crossref","unstructured":"Bearman S. The syndrome of hepatic venoocclusive disease after marrow transplantation. Blood. 1995; 85(11):3005-3020.","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005"},{"key":"20151","doi-asserted-by":"crossref","unstructured":"Richardson PG, Smith AR, Triplett BM. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017; 178(1):112-118.","DOI":"10.1111\/bjh.14727"},{"key":"20152","doi-asserted-by":"crossref","unstructured":"Strouse C, Zhang Y, Zhang M-J. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2018; 24(10):2072-2080.","DOI":"10.1016\/j.bbmt.2018.06.013"},{"key":"20153","doi-asserted-by":"crossref","unstructured":"Salat C, Holler E, Kolb H-J. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997; 89(6):2184-2188.","DOI":"10.1182\/blood.V89.6.2184"},{"key":"20154","doi-asserted-by":"crossref","unstructured":"Tanikawa S, Mori S, Ohhashi K. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant. 2000; 26(8):881-886.","DOI":"10.1038\/sj.bmt.1702624"},{"key":"20155","doi-asserted-by":"crossref","unstructured":"Cutler C, Kim HT, Ayanian S. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010; 16(8):1180-1185.","DOI":"10.1016\/j.bbmt.2010.02.016"},{"key":"20156","doi-asserted-by":"crossref","unstructured":"Akil A, Zhang Q, Mumaw CL. Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21(10):1739-1745.","DOI":"10.1016\/j.bbmt.2015.07.004"},{"key":"20157","doi-asserted-by":"crossref","unstructured":"Piccin A, Sartori MT, Bisogno G. New insights into sinusoidal obstruction syndrome: microparticles and VOD. Intern Med J. 2017; 47(10):1173-1183.","DOI":"10.1111\/imj.13550"},{"key":"20158","doi-asserted-by":"crossref","unstructured":"Luft T, Benner A, Jodele S. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017; 4(9):e414-e423.","DOI":"10.1016\/S2352-3026(17)30108-4"},{"key":"20159","doi-asserted-by":"crossref","unstructured":"Zeisbrich M, Becker N, Benner A. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017; 52(10):1399-1405.","DOI":"10.1038\/bmt.2017.119"},{"key":"20160","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Stern M, Brand R. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009; 115(20):4715-4726.","DOI":"10.1002\/cncr.24531"},{"key":"20161","unstructured":"Center for International Blood & Marrow Transplant Research. VOD Risk Calculator. 2018. Publisher Full Text|"},{"key":"20162","doi-asserted-by":"crossref","unstructured":"Ruutu T, Eriksson B, Remes K. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002; 100(6):1977-1983.","DOI":"10.1182\/blood-2001-12-0159"},{"key":"20163","doi-asserted-by":"crossref","unstructured":"Ruutu T, Juvonen E, Remberger M. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014; 20(1):135-138.","DOI":"10.1016\/j.bbmt.2013.10.014"},{"key":"20164","doi-asserted-by":"crossref","unstructured":"Cheuk DKL, Chiang AKS, Ha SY, Chan GCF. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015; 5:CD009311.","DOI":"10.1002\/14651858.CD009311.pub2"},{"key":"20165","doi-asserted-by":"crossref","unstructured":"Lahera V, Goicoechea M, de Vinuesa SG. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007; 14(2):243-248.","DOI":"10.2174\/092986707779313381"},{"key":"20166","doi-asserted-by":"crossref","unstructured":"Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009; 203(2):325-330.","DOI":"10.1016\/j.atherosclerosis.2008.08.022"},{"key":"20167","doi-asserted-by":"crossref","unstructured":"Dietrich S, Okun JG, Schmidt K. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versushost disease in the absence of statin therapy. Haematologica. 2014; 99(3):541-547.","DOI":"10.3324\/haematol.2013.090209"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9631\/70514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9631\/70515","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9631\/70514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:55:49Z","timestamp":1794045349000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.238790","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,23]]}}}